RÉSUMÉ
BACKGROUND: Intensive Care Resources are heavily utilized during the COVID-19 pandemic. However, risk stratification and prediction of SARS-CoV-2 patient clinical outcomes upon ICU admission remain inadequate. This study aimed to develop a machine learning model, based on retrospective & prospective clinical data, to stratify patient risk and predict ICU survival and outcomes. METHODS: A Germany-wide electronic registry was established to pseudonymously collect admission, therapeutic and discharge information of SARS-CoV-2 ICU patients retrospectively and prospectively. Machine learning approaches were evaluated for the accuracy and interpretability of predictions. The Explainable Boosting Machine approach was selected as the most suitable method. Individual, non-linear shape functions for predictive parameters and parameter interactions are reported. RESULTS: 1039 patients were included in the Explainable Boosting Machine model, 596 patients retrospectively collected, and 443 patients prospectively collected. The model for prediction of general ICU outcome was shown to be more reliable to predict "survival". Age, inflammatory and thrombotic activity, and severity of ARDS at ICU admission were shown to be predictive of ICU survival. Patients' age, pulmonary dysfunction and transfer from an external institution were predictors for ECMO therapy. The interaction of patient age with D-dimer levels on admission and creatinine levels with SOFA score without GCS were predictors for renal replacement therapy. CONCLUSIONS: Using Explainable Boosting Machine analysis, we confirmed and weighed previously reported and identified novel predictors for outcome in critically ill COVID-19 patients. Using this strategy, predictive modeling of COVID-19 ICU patient outcomes can be performed overcoming the limitations of linear regression models. Trial registration "ClinicalTrials" (clinicaltrials.gov) under NCT04455451.
Sujet(s)
COVID-19/épidémiologie , Maladie grave/épidémiologie , Dossiers médicaux électroniques/statistiques et données numériques , Unités de soins intensifs , Apprentissage machine , Adulte , Sujet âgé , COVID-19/thérapie , Études de cohortes , Maladie grave/thérapie , Service hospitalier d'urgences , Femelle , Allemagne , Humains , Mâle , Adulte d'âge moyen ,RÉSUMÉ
BACKGROUND: Large randomized trials are the best method to test the efficacy and safety of treatments expected to have moderate effects. We observed a significant decline in potential participants' response to mailed invitations to participate in such trials over a 10-year period and investigated possible reasons behind this and potential modifications to the invitation process to mitigate it. METHODS: Participants who declined to participate in the HPS2-THRIVE trial were asked to give a reason. Formal focus groups were conducted to explore the reasons that potential participants might have for not participating. In addition, two embedded randomized comparisons around the timing of provision of the full participant information leaflet (PIL) and its style were conducted during recruitment into this large randomized trial. HPS2-THRIVE is registered at ClinicalTrials.gov (NCT00461630). RESULTS: The commonest reason given for declining invitations related to mobility and transportation (despite the offer of travel expenses). Both the focus groups and potential participants who declined their invitation indicated concern about side-effects of the treatment (as presented in the PIL) as a reason for declining the invitation. Neither delaying provision of the full PIL until the potential participant attended the trial clinic, nor modifying the style of the PIL improved the proportion of potential participants entering the trial: odds ratio (OR) 1.05 (95% confidence interval (CI) 0.94-1.17) and 1.10 (95% CI 0.94-1.28), respectively. However, modifying the style of the PIL did increase the proportion of participants attending screening appointments (OR 1.17, 95% CI 1.03-1.33). CONCLUSIONS: Many reasons given for not participating in trials are not tractable to individual trials. However, modification of the PIL does show potential to modestly improve participation. If further trials could identify similar simple interventions that were beneficial, their net effects could substantially improve trial participation and facilitate recruitment into large trials.
Sujet(s)
Participation des patients , Sélection de patients , Essais contrôlés randomisés comme sujet , Sujet âgé , Sujet âgé de 80 ans ou plus , Groupes de discussion , Humains , Indoles/administration et posologie , Adulte d'âge moyen , Acide nicotinique/administration et posologie , Maladies vasculaires/prévention et contrôleRÉSUMÉ
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Sujet(s)
Acide acétylsalicylique/usage thérapeutique , Maladies cardiovasculaires/prévention et contrôle , Complications du diabète/prévention et contrôle , Diabète/traitement médicamenteux , Hémorragie/induit chimiquement , Antiagrégants plaquettaires/usage thérapeutique , Prévention primaire , Sujet âgé , Sujet âgé de 80 ans ou plus , Acide acétylsalicylique/effets indésirables , Maladies cardiovasculaires/épidémiologie , Complications du diabète/épidémiologie , Femelle , Études de suivi , Hémorragie/épidémiologie , Humains , Mâle , Adulte d'âge moyen , Antiagrégants plaquettaires/effets indésirables , Loi de Poisson , Facteurs de risqueRÉSUMÉ
BACKGROUND: Increased intake of n-3 fatty acids has been associated with a reduced risk of cardiovascular disease in observational studies, but this finding has not been confirmed in randomized trials. It remains unclear whether n-3 (also called omega-3) fatty acid supplementation has cardiovascular benefit in patients with diabetes mellitus. METHODS: We randomly assigned 15,480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease to receive 1-g capsules containing either n-3 fatty acids (fatty acid group) or matching placebo (olive oil) daily. The primary outcome was a first serious vascular event (i.e., nonfatal myocardial infarction or stroke, transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage). The secondary outcome was a first serious vascular event or any arterial revascularization. RESULTS: During a mean follow-up of 7.4 years (adherence rate, 76%), a serious vascular event occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P=0.55). The composite outcome of a serious vascular event or revascularization occurred in 882 patients (11.4%) and 887 patients (11.5%), respectively (rate ratio, 1.00; 95% CI, 0.91 to 1.09). Death from any cause occurred in 752 patients (9.7%) in the fatty acid group and in 788 (10.2%) in the placebo group (rate ratio, 0.95; 95% CI, 0.86 to 1.05). There were no significant between-group differences in the rates of nonfatal serious adverse events. CONCLUSIONS: Among patients with diabetes without evidence of cardiovascular disease, there was no significant difference in the risk of serious vascular events between those who were assigned to receive n-3 fatty acid supplementation and those who were assigned to receive placebo. (Funded by the British Heart Foundation and others; Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Sujet(s)
Maladies cardiovasculaires/prévention et contrôle , Complications du diabète/prévention et contrôle , Diabète/traitement médicamenteux , Acides gras omega-3/usage thérapeutique , Adulte , Sujet âgé , Acide acétylsalicylique/usage thérapeutique , Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/mortalité , Diabète/mortalité , Compléments alimentaires , Acides gras omega-3/effets indésirables , Femelle , Études de suivi , Humains , Estimation de Kaplan-Meier , Mâle , Adulte d'âge moyen , Antiagrégants plaquettaires/usage thérapeutique , Résultat thérapeutiqueRÉSUMÉ
The molecular underpinnings of invasion, a hallmark of cancer, have been defined in terms of individual mediators but crucial interactions between these mediators remain undefined. In xenograft models and patient specimens, we identified a c-Met/ß1 integrin complex that formed during significant invasive oncologic processes: breast cancer metastases and glioblastoma invasive resistance to antiangiogenic VEGF neutralizing antibody, bevacizumab. Inducing c-Met/ß1 complex formation through an engineered inducible heterodimerization system promoted features crucial to overcoming stressors during metastases or antiangiogenic therapy: migration in the primary site, survival under hypoxia, and extravasation out of circulation. c-Met/ß1 complex formation was up-regulated by hypoxia, while VEGF binding VEGFR2 sequestered c-Met and ß1 integrin, preventing their binding. Complex formation promoted ligand-independent receptor activation, with integrin-linked kinase phosphorylating c-Met and crystallography revealing the c-Met/ß1 complex to maintain the high-affinity ß1 integrin conformation. Site-directed mutagenesis verified the necessity for c-Met/ß1 binding of amino acids predicted by crystallography to mediate their extracellular interaction. Far-Western blotting and sequential immunoprecipitation revealed that c-Met displaced α5 integrin from ß1 integrin, creating a complex with much greater affinity for fibronectin (FN) than α5ß1. Thus, tumor cells adapt to microenvironmental stressors induced by metastases or bevacizumab by coopting receptors, which normally promote both cell migration modes: chemotaxis, movement toward concentrations of environmental chemoattractants, and haptotaxis, movement controlled by the relative strengths of peripheral adhesions. Tumor cells then redirect these receptors away from their conventional binding partners, forming a powerful structural c-Met/ß1 complex whose ligand-independent cross-activation and robust affinity for FN drive invasive oncologic processes.
Sujet(s)
Tumeurs du sein/secondaire , Résistance aux médicaments antinéoplasiques , Glioblastome/secondaire , Antigènes CD29/métabolisme , Protéines proto-oncogènes c-met/métabolisme , Inhibiteurs de l'angiogenèse/pharmacologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Bévacizumab/pharmacologie , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/métabolisme , Adhérence cellulaire/effets des médicaments et des substances chimiques , Mouvement cellulaire/effets des médicaments et des substances chimiques , Femelle , Fibronectines/métabolisme , Glioblastome/traitement médicamenteux , Glioblastome/métabolisme , Humains , Antigènes CD29/génétique , Souris , Invasion tumorale , Phosphorylation/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-met/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Cellules cancéreuses en culture , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
BACKGROUND: The relevance of vitamin D for prevention of cardiovascular disease is uncertain. The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial previously reported effects of vitamin D on plasma markers of vitamin D status, and the present report describes the effects on blood pressure, heart rate, arterial stiffness, and cardiac function. METHODS AND RESULTS: This was a randomized, double-blind, placebo-controlled trial of 305 older people living in United Kingdom, who were allocated vitamin D 4000 IU (100 µg), vitamin D 2000 IU (50 µg), or placebo daily. Primary outcomes were plasma concentrations of 25-hydroxy-vitamin D and secondary outcomes were blood pressure, heart rate, and arterial stiffness in all participants at 6 and 12 months, plasma N-terminal prohormone of brain natriuretic peptide levels in all participants at 12 months, and echocardiographic measures of cardiac function in a randomly selected subset (n=177) at 12 months. Mean (SE) plasma 25-hydroxy-vitamin D concentrations were 50 (SE 2) nmol/L at baseline and increased to 137 (2.4), 102 (2.4), and 53 (2.4) nmol/L after 12 months in those allocated 4000 IU/d, 2000 IU/d of vitamin D, or placebo, respectively. Allocation to vitamin D had no significant effect on mean levels of blood pressure, heart rate, or arterial stiffness at either 6 or 12 months, nor on any echocardiographic measures of cardiac function, or plasma N-terminal prohormone of brain natriuretic peptide concentration at 12 months. CONCLUSIONS: The absence of any significant effect of vitamin D on blood pressure, arterial stiffness, or cardiac function suggests that any beneficial effects of vitamin D on cardiovascular disease are unlikely to be mediated through these mechanisms. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrialsregister.eu/ctr-search/search. Unique identifier: EudraCT number: 2011-005763-24a.
Sujet(s)
Fonction auriculaire gauche/effets des médicaments et des substances chimiques , Pression sanguine/effets des médicaments et des substances chimiques , Maladies cardiovasculaires/prévention et contrôle , Compléments alimentaires , Rigidité vasculaire/effets des médicaments et des substances chimiques , Fonction ventriculaire gauche/effets des médicaments et des substances chimiques , Vitamine D/administration et posologie , Facteurs âges , Sujet âgé , Vieillissement , Marqueurs biologiques/sang , Maladies cardiovasculaires/sang , Maladies cardiovasculaires/imagerie diagnostique , Maladies cardiovasculaires/physiopathologie , Compléments alimentaires/effets indésirables , Méthode en double aveugle , Échocardiographie , Angleterre , Femelle , Rythme cardiaque/effets des médicaments et des substances chimiques , Humains , Mâle , Peptide natriurétique cérébral/sang , Fragments peptidiques/sang , Facteurs temps , Résultat thérapeutique , Vitamine D/effets indésirables , Vitamine D/analogues et dérivés , Vitamine D/sangRÉSUMÉ
Clinical trials revealed limited response duration of glioblastomas to VEGF-neutralizing antibody bevacizumab. Thriving in the devascularized microenvironment occurring after antiangiogenic therapy requires tumor cell adaptation to decreased glucose, with 50% less glucose identified in bevacizumab-treated xenografts. Compared with bevacizumab-responsive xenograft cells, resistant cells exhibited increased glucose uptake, glycolysis, 13C NMR pyruvate to lactate conversion, and survival in low glucose. Glucose transporter 3 (GLUT3) was upregulated in bevacizumab-resistant versus sensitive xenografts and patient specimens in a HIF-1α-dependent manner. Resistant versus sensitive cell mitochondria in oxidative phosphorylation-selective conditions produced less ATP. Despite unchanged mitochondrial numbers, normoxic resistant cells had lower mitochondrial membrane potential than sensitive cells, confirming poorer mitochondrial health, but avoided the mitochondrial dysfunction of hypoxic sensitive cells. Thin-layer chromatography revealed increased triglycerides in bevacizumab-resistant versus sensitive xenografts, a change driven by mitochondrial stress. A glycogen synthase kinase-3ß inhibitor suppressing GLUT3 transcription caused greater cell death in bevacizumab-resistant than -responsive cells. Overexpressing GLUT3 in tumor cells recapitulated bevacizumab-resistant cell features: survival and proliferation in low glucose, increased glycolysis, impaired oxidative phosphorylation, and rapid in vivo proliferation only slowed by bevacizumab to that of untreated bevacizumab-responsive tumors. Targeting GLUT3 or the increased glycolysis reliance in resistant tumors could unlock the potential of antiangiogenic treatments.
Sujet(s)
Inhibiteurs de l'angiogenèse/usage thérapeutique , Bévacizumab/usage thérapeutique , Résistance aux médicaments antinéoplasiques/génétique , Glioblastome/traitement médicamenteux , Transporteur de glucose de type 3/génétique , Glycolyse , Inhibiteurs de l'angiogenèse/pharmacologie , Animaux , Bévacizumab/pharmacologie , Lignée cellulaire tumorale , Survie cellulaire , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Glioblastome/vascularisation , Glioblastome/génétique , Glioblastome/métabolisme , Glucose/métabolisme , Transporteur de glucose de type 3/effets des médicaments et des substances chimiques , Humains , Spectroscopie par résonance magnétique , Souris , Souris nude , Transplantation tumorale , Phosphorylation oxydative , Acide pyruvique/métabolisme , Régulation positiveRÉSUMÉ
BACKGROUND: Cardiac surgery-related acute kidney injury (AKI) is a common postoperative complication that greatly increases morbidity and mortality. There are currently no effective interventions to prevent AKI associated with cardiac surgery. Experimental data have shown that administration of the mineralocorticoid receptor blocker spironolactone prevents renal injury induced by ischemia-reperfusion in rats. The objective of this study was to test whether short-term perioperative administration of oral spironolactone could reduce the incidence of AKI in cardiac surgical patients. STUDY DESIGN: Randomized, double-blinded, placebo-controlled trial. SETTING & PARTICIPANTS: Data were collected from April 2014 through July 2015 at the National Heart Institute in Mexico. 233 patients were included; 115 and 118 received spironolactone or placebo, respectively. INTERVENTION: Spironolactone or placebo once at a dose of 100mg 12 to 24 hours before surgery and subsequently 3 further doses of 25mg in postoperative days 0, 1, and 2 were administered. OUTCOMES: Patients were followed up for 7 days or until discharge from the intensive care unit (ICU). The primary end point was AKI incidence defined by KDIGO criteria. Secondary end points included requirement of renal replacement therapy, ICU length of stay, and ICU mortality. Data were analyzed according to the intention-to-treat principle. RESULTS: Mean age was 53.2±15 years, mean serum creatinine level was 0.9±0.2mg/dL, median Thakar score for estimation of AKI risk was 2 (IQR, 1-3), and 25% had diabetes. The incidence of AKI was higher for the spironolactone group (43% vs 29%; P=0.02). No significant differences were found for secondary end points. LIMITATIONS: Single center, AKI was mostly driven by AKI stage 1, planned sample size was not achieved, and there was no renin-angiotensin-aldosterone system washout period. CONCLUSIONS: Our trial demonstrated that spironolactone was not protective for AKI associated with cardiac surgery and there may be a trend toward risk.
Sujet(s)
Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/prévention et contrôle , Procédures de chirurgie cardiaque/effets indésirables , Antagonistes des récepteurs des minéralocorticoïdes/usage thérapeutique , Complications postopératoires/étiologie , Complications postopératoires/prévention et contrôle , Spironolactone/usage thérapeutique , Méthode en double aveugle , Femelle , Humains , Unités de soins intensifs , Mâle , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Clinical trials require cost-effective methods for identifying, randomising, and following large numbers of people in order to generate reliable evidence. ASCEND (A Study of Cardiovascular Events iN Diabetes) is a randomised '2 × 2 factorial design' study of aspirin and omega-3 fatty acid supplements for the primary prevention of cardiovascular events in people with diabetes; this study used central disease registers and a mail-based approach to identify, randomise, and follow 15,000 people. In collaboration with UK consultants and general practitioners (GPs), researchers identified potentially eligible people with diabetes from centrally held registers (e.g. for retinopathy screening) and GP-held disease registers. Permission was obtained under section 251 of the National Health Service Act 2006 (previously section 60 of the NHS act 2001) to allow invitation letters to be generated centrally in the name of the holder of the register. In addition, with the collaboration of the National Institutes for Health Research (NIHR) Diabetes and Primary Care Research Networks (DRN and PCRN), general practices sent pre-assembled invitation packs to people with a diagnosis of diabetes. Invitation packs included a cover letter, screening questionnaire (with consent form), information leaflet, and a Freepost envelope. Eligible patients entered a 2-month, pre-randomisation, run-in phase on placebo tablets and were only randomised if they completed a randomisation form and remained willing and eligible at the end of the run-in. Follow-up is ongoing, using mail-based approaches that are being supplemented by central registry data. RESULTS: Information on approximately 600,000 people listed on 58 centrally held diabetes registers was obtained, and 300,188 potentially eligible patients were invited to join the study. In addition, 785 GP practices mailed invitations to 120,875 patients. A further 2,340 potential study participants were identified via other routes. In total, 423,403 people with diabetes were invited to take part; 26,462 entered the 2-month, pre-randomisation, run-in phase; and 15,480 were randomised. CONCLUSION: If sufficient numbers of potentially eligible patients can be identified centrally and the trial treatments do not require participants to attend clinics, the recruitment and follow-up of patients by mail is feasible and cost-effective. Wider use of these methods could allow more, large, randomised trials to be undertaken successfully and cost-effectively. TRIAL REGISTRATION: Current Controlled Trials, ISRCTN60635500 , registered on 14 July 2005.
Sujet(s)
Acide acétylsalicylique/usage thérapeutique , Maladies cardiovasculaires/prévention et contrôle , Diabète/traitement médicamenteux , Compléments alimentaires , Acides gras omega-3/usage thérapeutique , Sélection de patients , Antiagrégants plaquettaires/usage thérapeutique , Service postal/économie , Prévention primaire/méthodes , Soutien financier à la recherche comme sujet/économie , Acide acétylsalicylique/effets indésirables , Maladies cardiovasculaires/diagnostic , Formulaires de consentement/économie , Analyse coût-bénéfice , Diabète/diagnostic , Compléments alimentaires/effets indésirables , Acides gras omega-3/effets indésirables , Humains , Antiagrégants plaquettaires/effets indésirables , Enregistrements , Taille de l'échantillon , Enquêtes et questionnaires/économie , Facteurs temps , Résultat thérapeutique , Royaume-UniRÉSUMÉ
BACKGROUND: Previous large trials of vitamin D for prevention of fractures and other disease outcomes have reported conflicting results, possibly because the doses tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) predicted by the observational studies. This report describes the design and baseline characteristics of the BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial which aims to establish the best dose of vitamin D to assess in a future large outcome trial. METHODS: The BEST-D trial will compare the biochemical and other effects of daily dietary supplementation with 100 µg or 50 µg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90 nmol/L between participants allocated 100 µg and participants allocated 50 µg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. RESULTS: About one-third of eligible participants agreed to participate in the trial. The mean age was 72 (SD 6) years with equal numbers of men and women. About one third reported a prior history of fracture or hypertension, one-fifth reported a prior cardiovascular event, and one tenth reported diabetes or a fall in the previous 6 months. CONCLUSIONS: The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer.
Sujet(s)
Chutes accidentelles/prévention et contrôle , Agents de maintien de la densité osseuse/administration et posologie , Cholécalciférol/administration et posologie , Fractures osseuses/prévention et contrôle , Sujet âgé , Pression sanguine/effets des médicaments et des substances chimiques , Densité osseuse/effets des médicaments et des substances chimiques , Agents de maintien de la densité osseuse/effets indésirables , Cholécalciférol/effets indésirables , Compléments alimentaires , Échocardiographie , Femelle , Force de la main , Coeur/effets des médicaments et des substances chimiques , Coeur/physiologie , Humains , Mâle , Plan de recherche , Rigidité vasculaire/effets des médicaments et des substances chimiques , Vitamine D/analogues et dérivés , Vitamine D/sangRÉSUMÉ
BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity. CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown. METHODS/DESIGN: The Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy (3C) Study is a multicentre, open-label, randomized controlled trial with 852 participants which is addressing two important questions in kidney transplantation. The first question is whether a Campath (alemtuzumab)-based induction therapy strategy is superior to basiliximab-based therapy, and the second is whether, from 6 months after transplantation, a sirolimus-based maintenance therapy strategy is superior to tacrolimus-based therapy. Recruitment is complete, and follow-up will continue for around 5 years post-transplant. The primary endpoint for the induction therapy comparison is biopsy-proven acute rejection by 6 months, and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation. The study is sponsored by the University of Oxford and endorsed by the British Transplantation Society, and 18 centers for adult kidney transplant are participating. DISCUSSION: Late graft failure is a major issue for kidney-transplant recipients. If our hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer. A positive outcome could change clinical practice in kidney transplantation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01120028 and ISRCTN88894088.
RÉSUMÉ
PURPOSE: To identify mediators of glioblastoma antiangiogenic therapy resistance and target these mediators in xenografts. EXPERIMENTAL DESIGN: We conducted microarray analysis comparing bevacizumab-resistant glioblastomas (BRG) with pretreatment tumors from the same patients. We established novel xenograft models of antiangiogenic therapy resistance to target candidate resistance mediator(s). RESULTS: BRG microarray analysis revealed upregulation versus pretreatment of receptor tyrosine kinase c-Met, which underwent further investigation because of its prior biologic plausibility as a bevacizumab resistance mediator. BRGs exhibited increased hypoxia versus pretreatment in a manner correlating with their c-Met upregulation, increased c-Met phosphorylation, and increased phosphorylation of c-Met-activated focal adhesion kinase and STAT3. We developed 2 novel xenograft models of antiangiogenic therapy resistance. In the first model, serial bevacizumab treatment of an initially responsive xenograft generated a xenograft with acquired bevacizumab resistance, which exhibited upregulated c-Met expression versus pretreatment. In the second model, a BRG-derived xenograft maintained refractoriness to the MRI tumor vasculature alterations and survival-promoting effects of bevacizumab. Growth of this BRG-derived xenograft was inhibited by a c-Met inhibitor. Transducing these xenograft cells with c-Met short hairpin RNA inhibited their invasion and survival in hypoxia, disrupted their mesenchymal morphology, and converted them from bevacizumab-resistant to bevacizumab-responsive. Engineering bevacizumab-responsive cells to express constitutively active c-Met caused these cells to form bevacizumab-resistant xenografts. CONCLUSION: These findings support the role of c-Met in survival in hypoxia and invasion, features associated with antiangiogenic therapy resistance, and growth and therapeutic resistance of xenografts resistant to antiangiogenic therapy. Therapeutically targeting c-Met could prevent or overcome antiangiogenic therapy resistance.
Sujet(s)
Inhibiteurs de l'angiogenèse/pharmacologie , Résistance aux médicaments antinéoplasiques , Néovascularisation pathologique/génétique , Protéines proto-oncogènes c-met/génétique , Protéines proto-oncogènes c-met/métabolisme , Transcriptome , Inhibiteurs de l'angiogenèse/usage thérapeutique , Animaux , Anticorps monoclonaux humanisés/pharmacologie , Anticorps monoclonaux humanisés/usage thérapeutique , Bévacizumab , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/génétique , Analyse de regroupements , Résistance aux médicaments antinéoplasiques/génétique , Activation enzymatique/génétique , Régulation de l'expression des gènes tumoraux , Glioblastome/traitement médicamenteux , Glioblastome/génétique , Glioblastome/métabolisme , Glioblastome/mortalité , Humains , Souris , Invasion tumorale/génétique , Néovascularisation pathologique/traitement médicamenteux , Protéines proto-oncogènes c-met/antagonistes et inhibiteurs , Interférence par ARN , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
INTRODUCTION: Acute kidney injury (AKI) associated with cardiac surgery is a common postoperative complication that increases the morbidity and mortality substantially. However, there is limited information of AKI after cardiac surgery in our institution. MATERIAL AND METHODS: We conducted a prospective, observational, and longitudinal analysis of adult patients that underwent to cardiac surgery requiring cardiopulmonary bypass and aortic cross clamp. Patients with preoperative chronic renal insufficiency that were on dialysis, with AKI detected up to 24 h before the procedure, or that received contrast agents 72 h before surgery were excluded. AKI was defined by the AKIN classification. Patients were followed up to 7 days after surgery or before if discharged from the intensive care unit. We analyzed age, sex, body mass index (BMI), co-morbilities, previous cardiac surgery, left ventricular ejection fraction, New York Heart Association class, type of procedure, cardiopulmonary bypass time, cross clamp time and bleeding. RESULTS: Our analysis included 164 patients submitted to cardiac surgery. In the follow up, 84% did not have AKI, 11% had AKIN 1 and 2 accompanied by increase in serum creatinine and 6% had AKIN 3. Patients with AKI were older, had a higher preoperative creatinine, plasma glucose level, and a lower left ventricular ejection fraction. All together patients with AKIN had a longer hospital stay and a higher mortality (p < 0.001). The preoperative use of insulin was associated with the development of AKI, and there was a higher number of patients with a New York Heart Association class III and IV for heart failure in the more sever forms of AKI (p = 0.01). The logistic regression analysis revealed that patients with a high preoperative blood urea nitrogen (> 20 mg/dL) creatinine level (> 1 mg/dL), uric acid (> 7 mg/dL) and lower albumin (< 4 g/dL) or lower intraoperative hemoglobin (< 8 g/dL) had a higher risk for postoperative AKI. CONCLUSIONS: The prevalence of AKI in our Institute is of 17%. Patients with AKIN 2 and 3 had a higher mortality and a longer stay in the intensive care unit. The major risk factors for AKI development were identified.
Sujet(s)
Atteinte rénale aigüe/épidémiologie , Procédures de chirurgie cardiaque , Complications postopératoires/épidémiologie , Atteinte rénale aigüe/sang , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/thérapie , Adulte , Facteurs âges , Sujet âgé , Glycémie/analyse , Indice de masse corporelle , Pontage cardiopulmonaire , Créatinine/sang , Complications du diabète/traitement médicamenteux , Complications du diabète/épidémiologie , Interventions chirurgicales non urgentes , Femelle , Études de suivi , Humains , Unités de soins intensifs/statistiques et données numériques , Durée du séjour/statistiques et données numériques , Mâle , Mexique/épidémiologie , Adulte d'âge moyen , Complications postopératoires/sang , Complications postopératoires/étiologie , Complications postopératoires/thérapie , Études prospectives , Traitement substitutif de l'insuffisance rénale/statistiques et données numériques , Facteurs de risque , Sérumalbumine/analyse , Facteurs sexuels , Débit systoliqueRÉSUMÉ
While anti-angiogenic therapy was initially greeted enthusiastically by the cancer community, initial successes with this therapeutic modality were tempered by the failure of angiogenesis inhibitors to produce sustained clinical responses in most patients, with resistance to the inhibitors frequently developing. We recently reported that hypoxia increases after the devascularization caused by anti-angiogenic therapy, consistent with the goals of these therapies, but that some tumor cells become resistant and survive the hypoxic insult elicited by anti-angiogenic therapy through autophagy by activating both AMPK and HIF1A pathways. These findings suggest that modulating the autophagy pathway may someday allow anti-angiogenic therapy to fulfill its therapeutic potential. However, further work will clearly be needed to develop more potent and specific autophagy inhibitors and to better understand the regulators of autophagy in malignant cells.
Sujet(s)
Inhibiteurs de l'angiogenèse/usage thérapeutique , Autophagie , Résistance aux médicaments antinéoplasiques , Tumeurs/traitement médicamenteux , Tumeurs/anatomopathologie , Inhibiteurs de l'angiogenèse/pharmacologie , Animaux , Autophagie/effets des médicaments et des substances chimiques , Hypoxie cellulaire/effets des médicaments et des substances chimiques , Essais cliniques comme sujet , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Humains , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Modèles biologiques , Tumeurs/vascularisation , Cellules souches tumorales/anatomopathologie , Microenvironnement tumoral/effets des médicaments et des substances chimiquesRÉSUMÉ
To sustain tumor growth, cancer cells must be able to adapt to fluctuations in energy availability. We have identified a single microRNA that controls glioma cell proliferation, migration, and responsiveness to glucose deprivation. Abundant glucose allows relatively high miR-451 expression, promoting cell growth. In low glucose, miR-451 levels decrease, slowing proliferation but enhancing migration and survival. This allows cells to survive metabolic stress and seek out favorable growth conditions. In glioblastoma patients, elevated miR-451 is associated with shorter survival. The effects of miR-451 are mediated by LKB1, which it represses through targeting its binding partner, CAB39 (MO25 alpha). Overexpression of miR-451 sensitized cells to glucose deprivation, suggesting that its downregulation is necessary for robust activation of LKB1 in response to metabolic stress. Thus, miR-451 is a regulator of the LKB1/AMPK pathway, and this may represent a fundamental mechanism that contributes to cellular adaptation in response to altered energy availability.
Sujet(s)
AMP-Activated Protein Kinases/métabolisme , Tumeurs du cerveau/enzymologie , Glioblastome/enzymologie , microARN/métabolisme , Protein-Serine-Threonine Kinases/métabolisme , Transduction du signal , Stress physiologique , AMP-activated protein kinase kinases , AMP-Activated Protein Kinases/génétique , Adaptation physiologique , Animaux , Tumeurs du cerveau/génétique , Tumeurs du cerveau/mortalité , Tumeurs du cerveau/anatomopathologie , Cellules COS , Protéines de liaison au calcium/métabolisme , Mouvement cellulaire , Prolifération cellulaire , Survie cellulaire , Chlorocebus aethiops , Activation enzymatique , Régulation de l'expression des gènes codant pour des enzymes , Régulation de l'expression des gènes tumoraux , Glioblastome/génétique , Glioblastome/mortalité , Glioblastome/anatomopathologie , Glucose/déficit , Cellules HeLa , Humains , Pronostic , Protein-Serine-Threonine Kinases/génétique , Transduction du signal/génétique , Stress physiologique/génétique , Facteurs temps , TransfectionRÉSUMÉ
Drug development in human chronic lymphocytic leukemia (CLL) has been limited by lack of a suitable animal model to adequately assess pharmacologic properties relevant to clinical application. A recently described TCL-1 transgenic mouse develops a chronic B-cell CD5(+) leukemia that might be useful for such studies. Following confirmation of the natural history of this leukemia in the transgenic mice, we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets (Bcl-2, Mcl-1, AKT, PDK1, and DNMT1), wild-type p53 status, and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL. We then demonstrated the in vivo clinical activity of low-dose fludarabine in transgenic TCL-1 mice with active leukemia. These studies demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of survival (P = .046) compared with control mice. Similar to human CLL, an emergence of resistance was noted with fludarabine treatment in vivo. Overall, these studies suggest that the TCL-1 transgenic leukemia mouse model has similar clinical and therapeutic response properties to human CLL and may therefore serve as a useful in vivo tool to screen new drugs for subsequent development in CLL.